| pubmed-article:9862057 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:9862057 | lifeskim:mentions | umls-concept:C0278488 | lld:lifeskim |
| pubmed-article:9862057 | lifeskim:mentions | umls-concept:C0144576 | lld:lifeskim |
| pubmed-article:9862057 | lifeskim:mentions | umls-concept:C0205390 | lld:lifeskim |
| pubmed-article:9862057 | lifeskim:mentions | umls-concept:C1708063 | lld:lifeskim |
| pubmed-article:9862057 | lifeskim:mentions | umls-concept:C2603343 | lld:lifeskim |
| pubmed-article:9862057 | pubmed:issue | 11 | lld:pubmed |
| pubmed-article:9862057 | pubmed:dateCreated | 1999-2-25 | lld:pubmed |
| pubmed-article:9862057 | pubmed:abstractText | Single-agent bi-weekly paclitaxel was studied as first-line metastatic treatment for breast cancer in a phase I-II trial. | lld:pubmed |
| pubmed-article:9862057 | pubmed:language | eng | lld:pubmed |
| pubmed-article:9862057 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9862057 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:9862057 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9862057 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9862057 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:9862057 | pubmed:month | Nov | lld:pubmed |
| pubmed-article:9862057 | pubmed:issn | 0923-7534 | lld:pubmed |
| pubmed-article:9862057 | pubmed:author | pubmed-author:CampbellCC | lld:pubmed |
| pubmed-article:9862057 | pubmed:author | pubmed-author:O'ReillySS | lld:pubmed |
| pubmed-article:9862057 | pubmed:author | pubmed-author:DunhamA CAC | lld:pubmed |
| pubmed-article:9862057 | pubmed:author | pubmed-author:AyersDD | lld:pubmed |
| pubmed-article:9862057 | pubmed:author | pubmed-author:RagazJJ | lld:pubmed |
| pubmed-article:9862057 | pubmed:author | pubmed-author:NakashimaLL | lld:pubmed |
| pubmed-article:9862057 | pubmed:author | pubmed-author:GelmonK AKA | lld:pubmed |
| pubmed-article:9862057 | pubmed:author | pubmed-author:ShenkierTT | lld:pubmed |
| pubmed-article:9862057 | pubmed:author | pubmed-author:TolcherAA | lld:pubmed |
| pubmed-article:9862057 | pubmed:author | pubmed-author:BryceCC | lld:pubmed |
| pubmed-article:9862057 | pubmed:author | pubmed-author:RiellySS | lld:pubmed |
| pubmed-article:9862057 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:9862057 | pubmed:volume | 9 | lld:pubmed |
| pubmed-article:9862057 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:9862057 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:9862057 | pubmed:pagination | 1247-9 | lld:pubmed |
| pubmed-article:9862057 | pubmed:dateRevised | 2006-11-15 | lld:pubmed |
| pubmed-article:9862057 | pubmed:meshHeading | pubmed-meshheading:9862057-... | lld:pubmed |
| pubmed-article:9862057 | pubmed:meshHeading | pubmed-meshheading:9862057-... | lld:pubmed |
| pubmed-article:9862057 | pubmed:meshHeading | pubmed-meshheading:9862057-... | lld:pubmed |
| pubmed-article:9862057 | pubmed:meshHeading | pubmed-meshheading:9862057-... | lld:pubmed |
| pubmed-article:9862057 | pubmed:meshHeading | pubmed-meshheading:9862057-... | lld:pubmed |
| pubmed-article:9862057 | pubmed:meshHeading | pubmed-meshheading:9862057-... | lld:pubmed |
| pubmed-article:9862057 | pubmed:meshHeading | pubmed-meshheading:9862057-... | lld:pubmed |
| pubmed-article:9862057 | pubmed:meshHeading | pubmed-meshheading:9862057-... | lld:pubmed |
| pubmed-article:9862057 | pubmed:year | 1998 | lld:pubmed |
| pubmed-article:9862057 | pubmed:articleTitle | A phase I-II study of bi-weekly paclitaxel as first-line treatment in metastatic breast cancer. | lld:pubmed |
| pubmed-article:9862057 | pubmed:affiliation | British Columbia Cancer Agency, Vancouver Centre, Canada. | lld:pubmed |
| pubmed-article:9862057 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:9862057 | pubmed:publicationType | Clinical Trial | lld:pubmed |
| pubmed-article:9862057 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
| pubmed-article:9862057 | pubmed:publicationType | Clinical Trial, Phase II | lld:pubmed |
| pubmed-article:9862057 | pubmed:publicationType | Clinical Trial, Phase I | lld:pubmed |
